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Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor
development. Because their expression is exclusive to cancer cells and their elimination
induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However,
specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9
technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy
through targeting of two introns of the genes involved in the rearrangement, allowing for
robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential,
we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine
kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach
presented here might open new horizons for the selective elimination of cancer cells.
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Despite advances in treatment, cancer continues to causeover nine million deaths worldwide each year. Indeed,there is still much to be learned about the biologic
behavior of cancer cells and molecular disease mechanisms. In
this sense, genome editing offers unprecedented opportunities to
further our knowledge of cancer biology and to fuel the devel-
opment of new preclinical models and more efficient and directed
strategies to eliminate cancer cells1. Unlike other genetic diseases
such as Duchenne muscular dystrophy or cystic fibrosis, cancer
development involves several genetic mutations that can dereg-
ulate multiple genes. In the context of cancer gene therapy, it is
clear that targeting a single gene is often insufficient to eliminate
cancer cells—yet, many types of cancers are addicted to the
presence of a single oncogenic event that can reprogram cells by
deregulating downstream molecular and (epi)-genetic programs2
and initiate tumorigenesis. This is the case for the so-called fusion
oncogenes (FOs), which are chimeric genes resulting from in-
frame fusions of the coding sequences of two genes involved in a
chromosomal rearrangement3. While the nature of the FOs may
be diverse, they are primarily classified as involving transcription
factors or tyrosine kinases. Silencing of FO transcripts has been
shown to inhibit tumor cell growth in vitro and in vivo4,5,
demonstrating FO addiction in many human cancers. Moreover,
genome-wide mutational studies—particularly in childhood
cancers—have provided additional support for some FOs as the
sole necessary genetic drivers for cancer initiation by revealing
silent mutational landscapes in FO-initiated tumors6,7.
FOs are recurrent genomic findings in human cancer and are
characterized by patient-specific genomic breakpoints that
occur in intronic regions, rarely disrupting coding sequences.
Analysis of data from The Cancer Genome Atlas suggests that
FOs drive the development of more than 16% of human can-
cers8, including mesodermal cancers (typically leukemias,
lymphomas and sarcomas). FOs have also been found in epi-
thelial cancers, including prostate9, colorectal10, breast11 or
melanoma12, and over 350 recurrent FOs involving >300 dif-
ferent genes have been identified to date13,14. Given their
restriction to cancer cells, FOs are attractive targets for directed
therapy; however, therapeutic targeting of specific FOs has
remained challenging due to the difficulties in specifically
recognizing and targeting the resultant chimeric protein, and
also because FO products are intracellular, necessitating effec-
tive intracellular approaches for delivery of therapeutic mole-
cules targeting the chimeric transcripts/proteins15. Along this
line, small molecules16, intrabodies17 and aptamers18 have been
used successfully to target fusion proteins, and antisense
RNA19, ribozymes20 and RNAi21 to target the fusion tran-
scripts. Likewise, the development of genome editing approa-
ches offers new possibilities to directly target and modify the
genomic sequence of cancer cells22.
Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR)/Cas9-based technology has revolutionized genome
editing of mammalian cells, and can generate targeted breaks at
any desired location in the genome—opening new horizons for
therapeutic gene editing to correct monogenic or somatic
mutations23,24. CRISPR/Cas9 induced breaks can be repaired by
one of two major double-strand break (DSB) repair pathways: the
inefficient but error-free homology-directed repair (HDR) path-
way, which requires a DNA template; and the highly efficient but
error-prone non-homologous end joining (NHEJ) pathway,
which does not require a DNA template. A recent pioneering
study by Chen et al. exploited the HDR repair pathway to insert a
suicide gene at patient-specific breakpoints of FOs in prostate and
hepatocellular cancer cell lines25. Although very elegant, the
combination of an extremely low efficiency (1–10%) HDR-based
approach26 and the requirement of patient-specific breakpoint
CRISPR tool development limits the utility of this strategy for
developing targeted cancer therapies.
In the present study, we report an efficient NHEJ CRISPR-
mediated genome editing strategy for targeting FOs, which we
believe represents a valid approach for directed elimination of
cancer cells harboring a given FO. The approach is based on
targeting two intronic sequences—one in each of the genes
involved in the FO—that induces a cancer cell-specific genome
deletion that eliminates key protein domains or changes the
reading frame of the FO. Notably, this gene editing-based
approach induces deletion only in cells harboring a FO without
affecting exonic sequences or protein expression of the germline
non-rearranged alleles. The same two single guide RNAs
(sgRNAs) allow the targeting of different isoforms or every
patient-specific breakpoint of a given FO, and is thus a universal
approach for cancer-associated FOs. In vitro analysis and patient-
derived xenograft (PDX) models show that delivery of CRISPR/
Cas9 components targeting a FO results in efficient and specific
tumor growth control. Our findings provide a proof-of-concept
for a highly efficient and non-breakpoint-specific genome editing
strategy-targeting FOs as an innovative approach for selective
elimination of cancer cells.
Results
CRISPR-mediated intronic targeting enables FO disruption.
Our rationale was to devise a genome editing approach to speci-
fically disrupt FOs in cancer cells that fulfils two strict criteria: i) it
would not affect the exonic sequences or the expression of wild-
type alleles involved in the rearrangement, and ii) it would be
feasible irrespective of the FO isoform or the patient-specific
breakpoint. To test this approach, we first used a cellular model of
Ewing sarcoma, one of the most common cancers in children/
adolescents characterized by a chromosomal translocation that
fuses the transactivation domain of the RNA-binding protein
EWSR1 to the DNA-binding domain of an ETS protein, most
commonly FLI1. The EWSR1-FLI1 (EF) fusion acts as a dominant
transcription factor, and cells are addicted to EF expression27–29.
Two main EF isoforms exist that fuse exon 7 of EWSR1 to either
exon 5 (EF type 2) or exon 6 of FLI1 (EF type 1)30–32.
We designed a strategy to induce EF-specific genomic deletion
targeting two genomic introns—one in each rearranged gene –
flanking the breakpoint introns. To target all isoforms of EF, four
sgRNAs were designed to target introns 3 and 6 of EWSR1 and
introns 6 and 8 of FLI1 (Fig. 1a and Supplementary Table 1).
sgRNAs were designed specifically to not disrupt described splice
acceptor or donor sites or transcription regulators such as
enhancers or silencers. We also confirmed that the sgRNA target
sites were not affected by common single nucleotide polymorph-
isms (SNPs) (Supplementary Fig. 1a, b). Targeted introns were
selected to generate large deletions including key functional
domains of the FO, to induce a frameshift event in the remaining
3′ region of the FLI1 gene, and to cover all the common hotspot
introns within the break cluster regions. Consequently, genomic
deletions will occur only in cells harboring the FO with both on-
target intronic regions in the same chromosome. Crucially,
intron-directed sgRNAs guarantee the germline configuration of
non-rearranged EWSR1 and FLI1 alleles, such that the expression
of wild-type alleles is preserved in healthy cells.
Using a single sgRNA lentiviral expression vector (pLV-
U6sgRNA-EFSCas9)33, we tested the efficiency of genomic
deletion with four combinations of sgRNAs (sgE3-sgF6, sgE3-
sgF8, sgE6-sgF6, sgE6-sgF8) in the A673 Ewing sarcoma cell line.
Sanger sequencing analysis of PCR products using oligonucleo-
tides flanking the targeted loci confirmed genomic deletions
(Supplementary Fig. 2a), and EF-targeted A673 cells showed a
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significantly blunted clonogenic capacity (51%, 62%, 49%, and
56%, respectively) irrespective of the sgRNA pair used (Supple-
mentary Fig. 2b). Cleavage with sgE3-sgF8 resulted in high
deletion efficiency, generating the largest (27.7 kb) EF deletion
and resulting in the complete loss of the EWSR1 transactivation
domain and a frameshift alteration of the entire FLI1 DNA-
binding region (Supplementary Fig. 3a). Accordingly, this
combination was chosen for further study. Notably, targeted
deep-sequencing of sgE3- or sgF8-targeted A673 cells revealed
62% and 66% insertion/deletion (indels) in EWSR1 and FLI1 on-
target sites, respectively (Supplementary Table 2a, b). For
subsequent targeting of EF, sgE3 and sgF8 were cloned into an
all-in-one expression plasmid34 (pLV-U6sgE3-H1sgF8-EFSCas9-
2A-eGFP; hereafter termed LVCas9_EF) expressing sgE3 and
sgF8 from the U6 and H1 RNApol III promoters, respectively,
together with the simultaneous expression of Cas9 and GFP
proteins separated by a 2A self-cleaving peptide (Fig. 1b).
CRISPR-mediated deletion selectively reduces FO products.
We first examined the capacity of LVCas9_EF to generate EF
deletions in A673 and also RD-ES Ewing sarcoma cells, which
harbor different EF isoforms. The pLV-U6sgNT-EFSCas9)33
single non-targeting vector (hereafter termed LVCas9_NT) was
used as a control (Supplementary Table 1). PCR analysis of the
genomic regions spanning the intronic cleavage sites
(Supplementary Table 1) revealed a PCR band verified by Sanger
sequencing both in A673 cells (Fig. 1c) and in RD-ES cells
(Supplementary Fig. 2c). Consistently, RT-PCR and western blot
analysis confirmed that the simultaneous expression of sgE3 and
sgF8 induced a robust loss of EF mRNA and protein, respectively
(Fig. 1d, e and Supplementary Fig. 2d). We designed a quanti-
tative qRT-PCR-based expression assay for FO to estimate rates
of deletion, and found a significant 4.5-fold decrease in FO
expression in edited A673 cells at day 3 post-transduction (p.t.)
(Supplementary Fig. 2e). Deep sequencing of the deletion PCR
amplicons indicated a preference (~60%) for precise ligation of
cut products (Supplementary Fig. 2f). Finally, targeted deep-
sequencing analysis revealed that EF-targeted human primary
mesenchymal stem cells (hMSC) cells perform accurate splicing
of EWSR1 exons. To rule out any possible bias in the use of a
non-targeting control, we also tested a second control plasmid
(LVCas9_dC1/2) targeting two unrelated genomic loci that gen-
erate two genomic DSB in two different chromosomes. Results
showed no changes to cell viability in transduced A673 cells
(Supplementary Table 1 and Supplementary Fig. 2g).
CRISPR FO targeting does not impair genomic stability. We
next evaluated whether our CRISPR-mediated EF targeting
strategy induces collateral genomic alterations. We used as wild-
type control clinically-relevant healthy hMSC, which are
a
Exons 1 2 3 4 5 6 7 5 6 7 8 9
EWSR1-FLI1
EWSR1 FLI1
Type 1  
Type 2  
sgRNAs  sgE3 sgE6 sgF6 sgF8
Gene  
LTR



















A673 LVCas9_EF A673 LVCas9_NT


























Fig. 1 Strategy and in vitro CRISPR-mediated disruption of EWSR1-FLI1. a Scheme representing type 1 and 2 EWSR1-FLI1 FOs, illustrating the genomic
structure with exon arrangement and sites of fusion. sgRNAs targeting introns 3 and 6 of EWSR1 and 6 and 8 of FLI1 are indicated. b Schematic
representation of the all-in-one lentiviral vector for simultaneous expression of two sgRNAs, Cas9 and eGFP regulated by the U6, H1, and EFS promoters.
c, Genomic PCR analysis of edited and control A673 cells using oligonucleotides flanking the DNA targeted by sgE3 and sgF8 (n= 3, independent studies).
The 300 bp PCR product denotes deletion of the DNA fragment between the loci targeted by sgE3 and sgF8. PCR analysis was performed on extracted
DNA of cells at day 2, 4, and 6 post-transduction (pt). ALBUMIN was used as an internal control of the PCR reaction. Bottom panel shows a representative
Sanger sequencing chromatogram of the PCR products. d RT-PCR products from edited and control A673 Ewing sarcoma cells (n= 3, independent
studies). Analysis was done using extracted RNA of cells at day 2, 4, and 6 pt. Arrows depict the sizes of wild-type (961 bp) and deleted (150 bp) RT-PCR
products. GAPDH was used as an internal control of the RT-PCR reaction. Bottom panel shows a representative Sanger sequencing chromatogram of RT-
PCR products. e Western blotting of EWSR1-FLI1 in A673 cells. Analysis was done using total protein extracted from cells at day 3, 6, and 10 post-
transfection using an antibody specific for FLI1. GAPDH was used as an internal control of the assay. LTR: Long term repeat; P2A: porcine teschovirus-1 2A
self-cleaving peptide; WPRE: Virus (WHP) posttranscriptional regulatory elements.
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considered the cell-of-origin for human sarcomas35. Sequencing
analysis of EF-targeted hMSCs confirmed the presence of a
repertoire of indels (~55% and 68%, EWSR1 and FLI1, respec-
tively) at the targeted regions (Supplementary Fig. 4a). To assess
possible side-effects that could affect proliferation of healthy cells,
we treated hMSCs with LVCas9_NT or LVCas9_EF, finding no
difference in proliferation rates in long-term culture (Supple-
mentary Fig. 4b). Also, hMSC transduced with LVCas9_EF did
not produce tumors when injected into immunosuppressed mice.
G-banding karyotype analysis 7 days after transduction revealed
no numerical or structural abnormalities in hMSC, irrespective of
the vector used (Supplementary Fig. 4c), and high-density gen-
ome-wide array comparative genomic hybridization (aCGH)
analysis confirmed no large copy number deletions across the
genome (Supplementary Fig. 4d). hMSCs were also negative for
EWSR1-FLI1 translocation products by FISH and PCR analysis at
15- and 30-days p.t. (Supplementary Fig. 4e, f and Table 1).
Finally, qRT-PCR analysis of edited hMSCs confirmed non-
significant variation in the levels of EWSR1 and FLI1 expression
(Supplementary Fig. 4g). To test for potential off-target cleavage
activity, we performed next-generation sequencing (NGS) of PCR
amplicons spanning the 50 more probable in silico-predicted off-
target sites of sgE3 and sgF8. The threshold percentage for off-
target activity was set at 0.10%, since this was the highest per-
centage of indel-containing reads in control samples, considering
as noise indel-containing reads below this percentage36. For every
off-target site analyzed, indel-containing reads represented less
than 0.10% of the total, with the exception of one predicted site
(Supplementary Table 3, Supplementary Fig. 4h). Although this
site showed indel-containing reads at a slightly higher frequency
(∼0.12%) than the threshold, the sequence variations found were
also present in both controls and edited samples, suggesting that
they were not bona fide Cas9 off-targets. Thus, targeted NGS
ruled out mutations in EF-targeted hMSCs, A673, and RD-ES
cells harvested 7 days after LVCas9_EF transduction. Overall,
these data show that the therapeutic targeting of the EF FO seems
highly specific and does not interfere with non-rearranged alleles
in human control healthy cells.
Targeting of a driver FO inhibits tumor cell growth in vitro.
We utilized in vitro assays to examine the functional con-
sequences of targeting EF. Transduction with LVCas9_EF, but
not with LVCas9_NT, resulted in a 65.5% and 93.9% decrease
in A673 and RD-ES cell growth, respectively (Fig. 2a, b), and a
60.5% and 70.3% decrease, respectively, in clonogenic capacity
(Fig. 2d, e). No changes were found in LVCas9_EF-transduced
control U2OS cells (non-EWSR1-FLI1) (Fig. 2c, f). Consistent
with the growth phenotype observations, EF-targeted cells had
higher levels (5–8-fold) of apoptosis, measured both by pro-
pidium iodide staining (subG1 cells, Fig. 2g) and caspase-3
analysis (Fig. 2h), than control transduced cells, suggesting that
CRISPR-mediated abrogation of EF is sufficient to inhibit the
survival, proliferation, and clonogenicity of EF-expressing
Ewing sarcoma cells in vitro. As the induction of two DSBs in
the same chromosome has been related to inversion events37,
we checked for the presence of this type of rearrangement in
A673 cells. PCR analysis revealed the presence of inversion
products at 3 days p.t.; however, inversion carrier cells were
lost during cell culture and no inversion products were
detectable at day 21 p.t. (Supplementary Fig. 2h). In silico
analysis predicted that an inversion of the FO targeted region
will produce a truncated protein similar to that induced by
DNA deletion (Supplementary Fig. 3a), which is compatible
with a similar mechanism of cell death of inversion carrier
cells.
FO deletion controls tumor growth in a xenograft model. We
chose adenovirus (AdV) vectors to test the in vivo applications of
the targeting approach because of their high gene transfer effi-
ciency, their ability to infect cancer cells, their capacity for large
DNA transgenes (allowing co-delivery of sgRNAs and Cas9
within single vector particles) and also because they do not
readily integrate into host genomes38. To test whether AdV-based
in vivo delivery of the FO-targeting CRISPR machinery can
control tumor growth, we subcutaneously injected A673 cells into
immunodeficient mice and allowed tumors to develop for 10 days
(~150 mm3 in size) (Fig. 3a). Tumors were then injected with 100
μL of PBS containing 2.5 × 109 plaque-forming units (pfu) of the
AdCas9_EF vector containing the same cassette as described
above for the LV vector (sgE3 and sgF8 together with Cas9 and
GFP proteins), or the equivalent non-targeting AdCas9_NT
control vector, or PBS, at day 10, 13, 16 and 19 (Fig. 3a). Results
revealed that compared with AdCas9_NT- or PBS-treated mice,
tumor size in AdCas9_EF-treated mice was reduced by ~70% at
sacrifice (1345.2 ± 685.2 and 1144.0 ± 213.1 vs 375.7 ± 114.9 mm3,
respectively, p < 0.01) (Fig. 3b, c). Immunohistochemistry analysis
showed a robust decrease in the number of Ki67+ cells in EF-
targeted tumor sections (90% and 88% vs 12%, p < 0.001) and an
increase in the number of apoptotic cells (9% and 10% vs 45%, p
< 0.001) (Fig. 3d, e). Of note, 40% of xenografted mice treated
with AdCas9_EF survived beyond day 80, whereas all PBS- or
AdCas9_NT-treated mice succumbed to the disease by day 40
(Fig. 3f). Hematoxylin and eosin (H&E) staining of tumors
revealed a significantly lower number of viable tumor cells and
more extensive necrotic regions in EF-targeted tumors (Supple-
mentary Fig. 5a). Immunohistochemistry for Cas9 confirmed
adenoviral delivery into the tumors (Fig. 3d). Immunohisto-
chemostry analysis of the tumors from AdCas9_EF-treated mice
showed the colocalization of adenovirus expression (Cas9
immunostaining) with high and low expression of caspase-3 and
Ki67, respectively (Fig. 3g). Because we used the Hds:Athymic
Nude-Foxn1nu mouse strain, which lacks T cells and shows a
partial defect in B cell development (with a weakened innate
immune system), we tested for the presence of tumor-infiltrating
CD45+ leukocyte cells. Results showed that the necrotic region
was surrounded by tumor-infiltrating murine CD45+ leukocytes
(Fig. 3g). Targeted deep-sequencing analysis of the tumors at
sacrifice revealed that EF-targeted xenografted tumors analyzed
6 weeks after AdV injection were composed of non-edited (85%)
or partially-edited (one locus; 12% of EWSR1 or 3% of FLI1)
cancer cells (Supplementary Table 2e, f). No cells harboring an EF
deletion were present in the tumors suggesting that CRISPR-
mediated abrogation of EF is sufficient to inhibit survival of
Ewing sarcoma cells in vivo. Furthermore, targeted deep-
sequencing of PCR amplicons covering the 50 most probable
predicted off-target sites associated with sgE3 and sgF8 ruled out
mutations in EF-targeted xenografted tumors analyzed 6 weeks
after AdV injection (Supplementary Table 3).
FO deletion controls tumor growth in PDX models. To further
investigate the utility of the approach, we used three patient-
derived xenograft (PDX) models of Ewing sarcoma. The models
were established by subcutaneous implantation of Ewing sarcoma
PDXs into immunodeficient mice, which were allowed to develop
for 12 days (tumors ~150 mm3 in size) (Fig. 4a). FISH analysis
showed the presence of the t(11;22) translocation (Supplementary
Fig. 5b). We next examined the capacity of FO targeted deletions
to reduce PDX growth by measuring tumor size. As described
earlier, EWSR1-FLI1 targeted therapy was administered by ade-
noviral delivery using 2.5 × 109 pfu of the AdCas9_EF in 100 μL
of PBS (or a PBS control) at day 12, 14, 16 and 19 (Fig. 4a).
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Results showed that tumors were >74% smaller in AdCas9_EF-
treated mice at sacrifice than in PBS-treated mice (334.87 ± 28.01
vs 1321.70 ± 249.77 mm3, p < 0.001) (Fig. 4b, c). Immunohis-
tochemistry analysis of tumor sections showed significantly fewer
Ki67+ cells in EF-targeted tumors (18% vs 73%, p < 0.001) and an
increased number of apoptotic cells (57% vs 1.5%, p < 0.001)
(Fig. 4d, e). H&E staining also revealed a significantly lower
number of viable tumor cells and more extensive necrotic regions
in EF-targeted tumors (Fig. 4d). Immunohistochemistry for Cas9
confirmed adenoviral delivery into the tumors (Fig. 4d). Of note,
100% of PDX mice treated with AdCas9_EF survived beyond day
52% and 50% beyond day 70, whereas all PBS control mice
succumbed to the disease by day 40 (Fig. 4f). Taken together,
these results show that in vivo adenoviral delivery of EF-targeting
CRISPR components controls sarcoma growth.
Combined deletion and chemotherapy enhances tumor
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Fig. 2 CRISPR-mediated targeting of EWSR1-FLI1 inhibits in vitro cell growth. a–c Growth rate assay curves of A673 (**p= 0.01), RD-ES (***p= 0.0005)
and U2OS edited (LVCas9_EF) and control (LVCas9_NT) cells. (n= 6 independent experiments). d–f Representative crystal violet staining of A673
(***p= 0.0003), RD-ES (**p= 0.0017) and U2OS experimental and control cells. Bottom panels show the statistical analysis of the number of colonies.
(n= 3 independent experiments). g Left panel shows DNA profile analysis by propidium iodide staining and flow cytometry. FlowJo v10.0.7 flow cytometry
analysis of DNA fragmentation by subG1 population (cells with fragmented DNA) quantification. The percentage of cellular apoptosis was calculated
using the percentage of the subG1 peak. Right panel shows graphical representation of subG1 analysis. (n= 4 independent experiments) *p= 0.027.
h Representative images of caspase-3-immunostained A673 cells. Scale bars, 50 μm. Right panel shows the percentage of caspase-3-positive cells per field
analyzed. (n= 520 (LVCas9_NT) and n= 613 (LVCas9-EF) cells examined over three independent experiments), ***p= 1.07e-9. The error bars indicate
the s.e.m. for the averages across the multiple experiments; p-values are represented (ns non-significant; *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001). Statistical are
two-tailed unpaired t-test.
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our genomic editing approach to efficiently eliminate cancer cells
and a standard-of-care chemotherapeutic option for Ewing sar-
coma with doxorubicin. We examined the additive effects of
combined doxorubicin and EF deletion both in vitro and in vivo.
Corresponding FO deletion and treatment of A673 cells with 0.05
μg/ml doxorubicin resulted in a greater reduction of cell viability
(50%) than single treatments (39% or 42% with AdCas9_EF or
doxorubicin treatment alone, respectively) (Fig. 5a). For in vivo
analysis, we utilized the xenograft models generated as described
earlier, divided into four treatment groups. Mice were treated
with 1.5 mg/kg doxorubicin (intraperitoneal injection, weekly, for
two weeks) or with 2.5 × 109 pfu of the AdCas9_EF or
AdCas9_NT virus in PBS (intratumour injection, at day 9, 12, 15,
and 18) (Fig. 5b). Three groups received monotherapy of
AdCas9_NT, doxorubicin or AdCas9_EF, while the remaining
group was treated with combined therapy (doxorubicin+
AdCas9_EF), and animals were monitored for 80 days. Results
showed that mice treated with combined therapy showed a
greater reduction in tumor size at sacrifice (92.12%, 115.28 ±
28.35 mm3) than mice treated with monotherapy (83.7%, 237.4 ±
47.39 mm3 AdCas9_EF or 70.4%, 433.05 ± 56.91 mm3 doxor-
ubicin) as compared with control mice (1463.82 ± 278.17 mm3)
(Fig. 5c). These results indicate that combined therapy is more
effective than monotherapy. Of note, 66% of xenografted mice
treated with combined therapy survived beyond day 80 compared
with 33% of AdCas9_EF-treated mice. By contrast, all the mice
that received doxorubicin monotherapy succumbed to the disease
by day 64 (Fig. 5d).
Validation as a method for elimination of FO-addicted cells.
To validate the editing strategy as a universal strategy for elim-
ination of FO-driven cancer cells, we applied the same approach
in a cellular model harboring BCR-ABL1 (BA), a classical tyro-




















































































































































































Fig. 3 Deletion of EWSR1-FLI1 inhibits tumor growth in xenografted models. a Diagram showing the approach for the in vivo xenograft treatment. A673
cells were subcutaneously injected into immunodeficient mice and tumors were allowed to develop (~150mm3 in size). Tumors were then injected with
AdCas9_EF edition vector, AdCas9_NT control vector or PBS at days 10, 13, 16, and 19. Mice were sacrificed when tumor volume reached 1500mm3.
b Tumor growth over 23 days of analysis. (PBS n= 6; AdCas9_NT n= 6; AdCas9_EF n= 15 animals), **p= 0.004. c Images of representative tumors.
d Representative immunostaining for Ki-67, caspase-3 and Cas9 in A673 experimental and control tumors (n= 3 independent samples). Scale bars, 50 μm.
e Statistical analysis of the percentage of Ki-67- (PBS vs AdCas9_EF ***p= 1e-8, AdCas9_NT vs AdCas9_EF ***p= 6e-9), caspase-3- (PBS vs AdCas9_EF
***p= 1e-5, AdCas9_NT vs AdCas9_EF ***p= 5e-5) and Cas9-positive cells. f Kaplan–Meier survival curve comparing mice treated with experimental and
control AdV or PBS. (PBS n= 4; AdCas9_NT n= 5; AdCas9_EF n= 10 animals), *p= 0.046. g Representative immunostaining for Cas9, Ki-67, caspase-3,
and CD45 in an AdCas9_EF-treated xenografted tumor. The error bars indicate the s.e.m. for the averages across the multiple experiments; p-values are
represented (ns non-significant; *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001). A two-tailed unpaired t-test was used for statistical analysis of b, d, and log-rank test
for f.
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Four sgRNAs targeting BCR intron 8 and ABL intron 1 regions
were designed to induce a 133.9 kb deletion of the BA FO
(Supplementary Table 1), resulting in an extensive deletion of the
BCR transactivation domain and a frameshift alteration of the
entire ABL1 DNA-binding domain (Fig. 6a and Supplementary
Fig. 3b). Four sgRNA combinations (sgB8.1-sgA1.1, sgB8.1-
sgA1.2, sgB8.2sgA1.1, and sgB8.2-sgA1.2) were cloned into the
pLV-U6BH1A-C9G vector as before, and were electroporated into
the BA-expressing CML cell line K562 (Fig. 6b). Electroporation
was chosen as the delivery method because of the low trans-
duction efficiency of lentiviral vectors in K562 cells39. All four
sgRNA combinations efficiently abrogated the expression of BA
as confirmed by RT-PCR and Sanger sequencing (Fig. 6c). For
any given sgRNA combination, electroporated K562 cells showed
a significant decrease (∼85%) in clonogenic capacity in vitro
(Fig. 6d) concomitant with an increase in apoptosis (3% vs 15%,
p < 0.001) relative to equivalent cells electroporated with a non-
targeting vector (Supplementary Fig. 6a). The use of a control
plasmid (LVCas9_dC3/4) targeting two unrelated genomic loci in
two different chromosomes ruled out any effects on cell viability
in K562-treated cells due to the induction of two DSBs (Sup-
plementary Table 1 and Supplementary Fig. 6b, c). Because
cleavage with sgB8.1-sgA1.1 resulted in the highest reduction in
colony formation and the highest percentage of apoptosis rate
this combination was chosen for further study. For subsequent
targeting of BA, sgB8.1 and sgA1.1 were cloned into an all-in-one
expression plasmid34 (pLVCas9_BA). Targeted deep-sequencing
of sgB8.1 or sgA1.1-targeted K562 cells revealed 85% and 82%
indels in BCR and ABL1 on-target sites, respectively (Supple-
mentary Table 2). Similarly, targeted deep-sequencing of PCR
amplicons covering the most probable predicted off-target sites
associated with sgB8.1 and sgA1.1 ruled out mutations in BA-
targeted K562 cells after pLVCas9_BA electroporation (Supple-
mentary Table 3). qRT-PCR analysis of FO expression at day 2
post-electroporation (p.e.) of pLVCas9_BA edited K562 cells used
to estimate rates of deletion revealed a significant 5.0-fold
decrease in FO expression (Fig. 6e). We also analyzed the pre-
sence of inversions in K562 cells as before. PCR analysis revealed
the presence of inversion products at 2 days p.e.; however,
inversion carrier cells were lost during cell culture and no
inversion products were detectable at day 7 p.e. (Supplementary
Fig. 6d). In silico analysis showed that an inversion of the FO
targeted region will produce a truncated protein similar to the one
induced by DNA deletion (Supplementary Fig. 3b). We used cord
blood-derived human hematopoietic progenitor hCD34+ cells as





































































































































































Fig. 4 Deletion of EWSR1-FLI1 inhibits tumor growth in PDX models. a Diagram showing the approach for the AdV-based in vivo treatment. PDXs were
implanted into immunosuppressed mice and tumors were allowed to develop (~150mm3 in size). Tumors were then injected with AdCas9_EF edition
vector or PBS control vector at days 12, 14, 16, and 19. Mice were sacrificed when tumor volume reached 1500mm3. b Tumor growth over the 40 days
following subcutaneous PDX implantation. (PBS n= 3; AdCas9_sgEF n= 9 animals) (***p= 3e-5). c Representative tumors of control and experimental
mice sacrificed 40 days after PDX implantation. d Representative images of histological H&E staining, Ki-67, caspase-3, and Cas9 immunostaining of A673
experimental and control cells. Scale bars, 500 μm (4×) or 50 μm (20×). e Percentage of Ki-67-(***p= 3e-6), caspase-3-(***p= 3e-5) and Cas9-positive
cells per field analyzed (***p= 4e-6). (n= 3 independent samples). f Kaplan–Meier survival curve comparing mice treated with experimental and control
AdV. (PBS n= 3; AdCas9_sgEF n= 9 animals), ***p= 0.0002. Plot shows medians and ranges; error bars indicate the s.e.m. for the averages across the
multiple experiments; p-values are represented (*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001). A two-tailed unpaired t-test was used for statistical analysis of
b, e, and log-rank test for f.
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CD34+ cells revealed no difference in proliferation in long-
term culture, suggesting no production of collateral cancer-
driven genomic alterations (Supplementary Fig. 6e). No BCR-
ABL1 translocation products were detected in cells by PCR or
FISH assays conducted at 15- and 30-days p.e. (Supplementary
Fig. 6f, g, Supplementary Table 1). We then evaluated whether
AdV delivery of the BA-targeting CRISPR machinery (sgB8.1-
sgA1.1) also controls the growth of BA-driven tumors in vivo.
Accordingly, K562 cells were subcutaneously injected into
immunodeficient mice and tumors were allowed to develop for
15 days (~150 mm3 in size) (Fig. 6f). Tumors were then injected
with 2.5 × 109 pfu of the AdCas9_BA editing vector or the
AdCas9_NT control vector at day 15, 18, and 21. Adenoviral
delivery of AdCas9_BA profoundly inhibited tumor growth,
resulting in an 88% decrease in tumor size at sacrifice (281 ± 63
vs 1152 ± 158 mm3 (p < 0.001) compared with control tumors
(Fig. 6g, h). Strikingly, 50% and 22% of xenografted mice
treated with AdCas9_BA were alive after 38 and 64 days,
respectively, whereas all AdCas9_NT-treated mice succumbed
to the disease by day 34 (Fig. 6i). As observed in the Ewing
sarcoma model, the efficiency of the AdCas9_BA editing vector
was also associated with a robust decrease in the number of
Ki67+ cells (82% vs 17%, p < 0.001) and an increase in apop-
totic cells (2.5% vs 10%, p < 0.05) (Supplementary Fig. 6h, i).
H&E staining also revealed a significantly lower number of
viable tumor cells and more extensive necrotic regions in BA-
targeted tumors (Supplementary Fig. 6h). A combinatorial
approach using BA deletion with a standard-of-care therapeutic
option in CML (imatinib, 0.105 μg/ml) resulted in a significant
reduction in K562 cell viability compared with any of the
treatments in monotherapy (Fig. 6j). Targeted deep-sequencing
analysis of the tumors at sacrifice revealed that BA-targeted
xenografted tumors analyzed 6 weeks after AdV injection were
composed of non-edited (94%) or partially-edited (one locus;
3% of BCR or ABL1) cancer cells (Supplementary Table 2g, h).
Taken together, these results confirm the efficacy of CRISPR-
mediated targeting of sarcoma (EF)- and leukemia (BA)-asso-





























































































































Fig. 5 Combined approach of EWSR1-FLI1 deletion with doxorubicin inhibits tumor growth in xenograft models. a WST-1 cell proliferation analysis of
A673 cell treated with CRISPR-deletion or doxorubicin as monotherapy, or as combined therapy and controls (n= 3 independent experiments)
(LVCas9_NT vs LVCas9_EF **p= 0.01, LVCas9_NT vs Dox **p= 0.002, LVCas9_NT vs Dox+ LVCas9_NT **p= 0.005, LVCas9_NT vs Dox+
LVCas9_EF ***p= 0.0001). b Diagram showing the approach for the in vivo xenograft treatment. A673 cells were subcutaneously injected into
immunodeficient mice and tumors were allowed to develop (~150mm3 in size). Tumors were then injected with AdCas9_EF edition vector, doxorubicin
(DOX), AdCas9_NT control vector or their combination at days 9, 12, 15, and 18. Mice were sacrificed when tumor volume reached 1500mm3. c Tumor
growth over the 19 days following subcutaneous cells implantation. (AdCas9_NT n= 5; AdCas9_sgEF n= 6; DOX n= 6, DOX+AdCas9_EF n= 6 animals)
(AdCas9_NT vs DOX **p= 0.003, AdCas9_NT vs AdCas9_EF ***p= 9e-4, AdCas9_NT vs DOX+AdCas9_EF ***p= 5e-4). d Kaplan–Meier survival
curve comparing mice treated with CRISPR-deletion or DOX as monotherapy, or as combined therapy and controls. (AdCas9_NT n= 5; AdCas9_sgEF n=
6; DOX n= 6, DOX+AdCas9_EF n= 6 animals) (DOX+AdCas9_EF vs AdCas9_EF *p= 0.035, DOX+AdCas9_EF vs DOX **p= 0.003, DOX+
AdCas9_EF vs AdCas9_NT ***p= 0.0007). Plot shows medians and ranges; error bars indicate the s.e.m. for the averages across the multiple
experiments; p-values are represented (*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001). A two-tailed unpaired t-test was used for statistical analysis of a, c, and Log-
rank test for d.
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Discussion
FOs are ideal therapeutic targets for the development of new
directed cancer treatments, owing to their cancer-driving roles,
their restriction to cancer cells and the reliance of tumors on
them. Unfortunately, FOs are challenging to target directly with
candidate drugs, and although some successful anti-cancer drugs
have been developed based on the ability to target FOs40,41, the
development of new therapies are still needed. The ability to
precisely manipulate cancer cell genomes to correct or eliminate
cancer-causing aberrations by highly-efficient CRISPR/Cas9
genome editing opens new possibilities to develop FO-targeted
options to eliminate cancer cells. In the present study, we describe
a simple and efficient genome editing strategy specifically tar-
geting FOs in cancer cells. Our CRISPR/Cas9-based approach
a
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induces two targeted intronic DSBs in both genes involved in a
FO that, importantly, produces a cancer cell-specific genomic
deletion that is dependent on the presence of the FO, and has no
effect on wild-type gene expression in non-cancer cells. By tar-
geting two established FOs, involving either a transcription factor
(EF) or a tyrosine kinase (BA), we present a proof-of-concept
demonstration supporting the efficacy of genome edition to
eliminate cancer cells addicted to FOs. Exploiting an adenoviral
in vivo delivery of CRISPR components, we further demonstrate
that CRISPR/Cas9-mediated deletion in advance PDX cancer
models results in efficient induction of cancer cell death and
reduces tumor burden and mortality. Finally, we show that tar-
geted CRISPR-based FO deletion combined with chemotherapy
agents has an additive/synergistic effect on cell viability, tumor
growth and overall survival when used in xenograft models. In
the long term, this approach may provide an attractive strategy to
eliminate cancer cells and we believe our findings might have
applicability to other FOs beyond EF and BA. Due to the complex
genomic scenario in cancer cells, including co-existence of other
oncogenes, tumor suppressor genes, DNA damage response and
DNA repair pathways alterations, a case-by-case FO study could
shed light to the applicability of the strategy to eliminate different
types of cancer cells.
A recent study has described an approach for targeting FOs
using CRISPR/Cas9-based editing and the HDR DNA repair
mechanism. The strategy involves directly targeting the patient-
specific breakpoint to introduce a suicide gene into the genome of
cancer cells25. Notably, this elegant approach is based on poorly
efficient and breakpoint-specific design. Our system offers unique
advantages over breakpoint-targeted approaches. First, it exploits
the efficient NHEJ pathway active in all cell types, making the
design simple and highly efficient42, as shown here with high
efficiency targeting FOs for in vivo elimination of cancer cells
with significant decreases in tumor volume and increases in
survival rates. Second, the strategy targets two introns flanking all
breakpoint regions described in patients, making it a universal
approach for all cancer cells harboring a given FO irrespective of
the FO isoform or the patient-specific breakpoint. For those
promiscuous FOs (such as EWSR1) that have been described
rearranged with many different fusion partners, a combination of
the original 5′ sgRNA with a set of pre-designed 3′ sgRNAs will
cover all the possible FO family31. Third, our approach does not
affect exonic sequences or the expression of wild-type alleles
involved in the rearrangement.
CRISPR/Cas9-mediated genome editing could be a potential
platform for cancer treatment; however, (i) targeting efficiencies,
(ii) off-target effects, and (iii) in vivo delivery remain technical
limitations. As described in the present study, combinatorial
approaches using gene editing with other therapeutic options
(e.g., chemotherapy) further increases the efficacy of this
approach, allowing better responses with lower chemotherapy
doses for the elimination of cancer cells. In contrast to che-
motherapy agents, which can be damaging to normal tissues, we
show that the CRISPR approach is completely specific for the
elimination of cancer cells43,44. Potential off-target events at
unintended genomic sites remain important concerns that must
be investigated rigorously to ensure short- and long-term safety of
any gene-editing approach. We have used in vitro and in vivo
assays to study the potential effect of collateral cancer-driver
genomic alterations. Even though our results did not show pro-
liferation differences, these experiments are limited, and further
analysis will be needed to rule out the appearance of cancer-
driven off-target modifications. Although the CRISPR-based
toolbox supports diverse operations ranging from DNA and
RNA editing to gene expression modulation, delivery remains a
bottleneck for therapy development45. AdV vectors are a com-
monly utilized delivery vector in mouse models; they are ideal
for delivery of the entire CRISPR/Cas9 system in one vector,
with high transfection efficacy and they limit potential off-target
effects because their genome does not integrate into the host
genome46–48. Although the initially encountered high immuno-
genicity inhibited their widespread use to treat genetic disorders,
the overall picture changed when it was recognized that adeno-
viral infection in a tumor can activate a robust immunogenic
response, creating new opportunities in cancer therapy49,50. The
number of clinical trials using oncolytic AdVs is increasing, and
at present more than 32 trials are underway in different phases
(https://clinicaltrials.gov)51. As in our study, the main delivery
pathway used in these clinical trials is local administration
(intratumoral injection), which shows no toxicity at specific doses
and, in addition to the therapeutic effect, triggers an antitumor
immune response with therapeutic effects even on not-injected
distal tumors52. Our Hds:Athymic Nude-Foxn1 animal model
characterized by partial defects in B cell development shows
tumor-infiltrating CD45+mouse leukocyte cells in the tumor.
Nevertheless, additional studies on immunocompetent syngeneic
mouse models could yield information about the role of AdVs as
a delivery tool in cancer therapy. In the present study, we used
adenoviral-based in vivo delivery of the CRISPR/Cas9 compo-
nents as a proof-of-concept; however, we envision that other
delivery platforms such as AAVs and non-viral (polymeric and
liposome-based) vectors could be exploited to deliver the system
Fig. 6 Strategy validation in CML-initiating BCR-ABL model. a Schematic representation of the BCR-ABL1 locus showing the sgRNAs targeting introns 8 of
BCR and 1 of ABL1. b Schematic illustration of the vector and the approach for in vitro treatment. c Agarose gel electrophoresis of BCR-ABL RT-PCR
products obtained from experimental and control K562 cells electroporated with four combinations of sgRNAs. RT-PCR analysis was done using RNA
extracted from cells at day 2 post-nucleofection. Arrows depict the sizes of wild-type (1125 bp) and deleted (458 bp) RT-PCR products. GAPDH was used
as an internal control of the RT-PCR reaction. Bottom panel shows a representative chromatogram of Sanger sequencing analysis of the RT-PCR products.
d, Representative images and graphical representation of colony formation of K562 experimental and control cells (stained with nitrotetrazolium blue).
(n= 3 independent experiments). sgNT vs sgB8.1-agA1.1 ***p= 3e-10, sgNT vs sgB8.1-agA1.2 ***p= 5e-4, sgNT vs sgB8.2-sgA1.1 ***p= 3e-4, sgNT vs
sgB8.2-agA1.2 ***p= 1e-4. e BCR1-ABL expression level analysis. Relative expression level of BCR-ABL1 in control (LVCas9_NT) and treated (LVCas9_EF)
K562 cells measured by qRT-PCR and normalized to GUSB (n= 6 independent experiments, **p= 0.0020). f Diagram of xenograft production, adenoviral
treatment and tumor growth over the 30 days following subcutaneous cell injection and four in vivo adenoviral treatments. (AdCas9_NT n= 10;
AdCAas9_sgBA n= 10). g Representative tumors of control and experimental mice. h Tumor growth curve over the 28 days of study. (AdCas9_NT n= 10;
AdCas9_sgBA n= 10, ***p= 3e-4). i Kaplan–Meier survival curve comparing mice treated with experimental and control adenoviral vectors (AdCas9_NT
n= 10; AdCas9_sgBA n= 10 animals, ****p < 0.0001). j WST-1 cell proliferation analysis of K562 cell treated with CRISPR-deletion or imatinib (IM) as
monotherapy, or as combined therapy and controls (n= 3 independent experiments), K562 vs LVCas9_BA ***p= 3.9e-5, K562 vs IM *p= 0.043, K562 vs
IM+ LVCas9_NT **p= 0.006, K562 vs IM+ LVCas9_BA ***p= 4e-6. Plot shows medians and ranges; error bars indicate the s.e.m. for the averages
across the multiple experiments; p-values are represented (*p≤ 0.05, **p≤ 0.01, ***p≤ 0.001). A two-tailed unpaired t-test was used for statistical
analysis of d, e, h and j, and Log-rank test for i.
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to tumor cells. Further development of safer and robust delivery
systems and the refinement of genome editing technologies will
ultimately ensure optimal targeting efficiencies and safety
required for the potential clinical application of this cancer cell-
directed therapy.
Overall, our data demonstrate that NHEJ CRISPR-mediated
FO deletion is a selective and efficient strategy for cancer cell
elimination, providing a valuable tool for basic research and could
represents a promising strategy with therapeutic potential.
Methods
sgRNA design and generation of lentiviral constructs. sgRNAs were designed
using the online Benchling CRISPR gRNA Design tool (http://www.benchling.
com). The sgRNAs chosen were based on a high specificity rank and a low
potential off-target score53. The parental Streptococcus pyogenes Cas9 expression
lentiviral single and double sgRNAs expression vectors, pLV-sgRNA-Cas9 and
pLV-U6#1-H1#2-C9G, respectively, have been described33,34. sgRNAs were cloned
using synthetic gBlock fragments (IDT) that were digested with PacI and XhoI
(NEB) to facilitate cloning into the lentiviral backbone. When two different guides
were used, the first was cloned under the control of the U6 promoter and the
second was cloned under the control of the H1 promoter. The sequences for
sgRNAs, gBlocks, and primers used are listed in Supplementary Table 1. All
transformations were performed in Stbl3 bacteria (Thermo Fisher Scientific).
Cell culture. HEK293T/17 (CRL-11268), A673 (CRL-1598), umbilical cord blood-
derived hMSC (PCS-500-010), U2OS (HTB-96), and K562 (CCL-243) cells were
purchased from the American Type Culture Collection (ATCC). RD-ES cells were
a gift from Dr. Javier Alonso (Instituto Salud Carlos III, Madrid). HEK293T/17,
U2OS, and A673 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Lonza) and K562 and RD-ES cells were maintained in Roswell Park
Memorial Institute (RPMI) medium (Gibco); all were supplemented with 1%
Glutamax (Life Technologies), 10 mg/ml antibiotics (penicillin and streptomycin,
P/S, Gibco) and 10% fetal bovine serum (FBS, Life Technologies). hMSCs were
cultured in MesenPRO RS media (Thermo Fisher Scientific) supplemented with 1%
Glutamax (Life Technologies) and 10 mg/ml antibiotics (P/S, Gibco). hCD34+
were obtained freshly from the umbilical cord blood of healthy donors after
informed consent was obtained and after approval by the Cord Blood Bank
Transfusion Center of the Community of Madrid. Mononuclear cells were purified
by gradient centrifugation (Histopaque, Sigma-Aldrich) and hCD34+ cells were
purified by separation using magnetic beads (Miltenyi Biotec)54. hCD34+ cells
were cultured in StemSpan SFEM II (StemCell Technologies) containing 100 U/
mL P/S and a cytokine cocktail composed of 100 ng/mL of human stem cell factor
(hSCF) human FMS-like tyrosine kinase 3 (hFlt3L) and human thrombopoietin
(hTPO) and 10 ng/mL of human interleukin 3 (hIL3) (all from Preprotech). Cells
were cultured at 37 °C at 5% CO2, 5% O2 atmosphere in a humidified incubator. All
cell lines were periodically tested for mycoplasma contamination.
Lentivirus generation, titration, transduction. Recombinant lentiviruses were
produced by transient plasmid transfection of HEK293T/17 cells55. Briefly, cells
were seeded at 1.1 × 107 cells/dish in 15-cm dishes the day before transfection, and
were transfected by the calcium-phosphate method using 14.6 and 7.9 μg of
second-generation packaging plasmids (psPAX2 and pMD.2G, Addgene #12260
and #12259, respectively) and 22.5 μg of the appropriate transfer plasmid
depending on the experiment. The medium was collected after 48 h, cleared by
low-speed centrifugation, and filtered through 0.45 μm PVDF filters (Millipore).
Viral stocks were concentrated by ultracentrifugation in a Beckman LE ultra-
centrifuge using a SW28 rotor at 20,000 × g for 2 h at 4 °C. Pellets containing
lentivirus were air dried and resuspended overnight at 4 °C in 300 μL of sterile
NaCl 0.9% solution (B.Braun). Viral titers were calculated by FACS analysis on
transduced HEK293T cells when vectors expressed fluorescent proteins (trans-
duction units/mL) and particles quantified by qPCR in supernatants (particles/mL),
and were between 107 and 108 TU/mL. Viral aliquots were stored at −80 °C. Target
cells were re-plated 24 h before transduction and transduced using a multiplicity of
infection between 2 and 5. Cells were incubated at 37 °C for 6 h and then viral
supernatant were replaced with fresh media.
In vitro colony forming assays. For A673, RD-ES and U2OS cells, colony forming
assays were performed 24 h after transduction with the corresponding lentiviral
vectors in six-well plates (500 cells/well)56. Cells were allowed to grow for
14–21 days, after which cells were fixed using methanol solution and stained with a
0.5% crystal violet solution (Sigma-Aldrich) and counted. For K562 cells,
methylcellulose (StemCell Technologies) assays were performed by seeding 500
cells into 35-mm tissue culture dishes (ThermoFisher Scientific) 24 h after elec-
troporation. Colonies were stained two weeks later with Nitrotetrazolium Blue
chloride solution (NBT, Sigma-Aldrich) for 1 h at 37 °C and counted. All assays
were performed in triplicate and repeated three times.
Apoptotic SubG1 cell detection. Cell cycle distribution was analyzed by mea-
suring the DNA content using flow cytometry. Exponentially growing transduced
cells were pelleted by centrifugation, washed with PBS (Sigma-Aldrich), resus-
pended in ice-cold 70% ethanol (Sigma-Aldrich) in PBS for fixation, and were
maintained at 4 °C for 24 h. Prior to analysis, fixed cells were washed with
phosphate-citrate buffer (Sigma-Aldrich) and incubated with propidium iodide
staining solution (Sigma-Aldrich) containing 100 μg/mL of RNase (Qiagen) for 30
min. Cellular DNA content was measured using a BD FACSCantoTM platform (BD
Biosciences) and analyzed by using FlowJo® software (version 10.0.6, FlowJo).
PCR, RT-PCR, and qRT-PCR analysis. Genomic DNA and total RNA were
extracted using standard procedures with the DNeasy Blood and Tissue Kit or the
RNeasy Purification Kit, respectively (Qiagen). DNA and RNA were quantified by
spectrophotometry. cDNA was generated from 1 μg of total RNA using the High-
Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). PCR and RT-
PCR amplification were performed using Q5 High-Fidelity DNA Polymerase
(NEB). qRT-PCR was performed in 384-well plates with 2x SYBR Green Master
Mix (Applied Biosystems) using a QuantStudio 6 Detection System (Applied
Biosystems). Expression levels were normalized to the housekeeping genes
ALBUMIN for genomic DNA PCR and GAPDH for RT-PCR or GUSB for qRT-
PCR. The primers used are listed in Supplementary Table 1.
Western blotting. Proteins were extracted using standard procedures in the
presence of protease inhibitors57. Protein lysates were fractionated by SDS-PAGE
and transferred to PVDF membranes (Millipore) using TransFi (ThermoFisher
Scientific). Membranes were probed for FLI1 with a mouse monoclonal antibody
(1/400; BD Pharmigen). GAPDH was used as a loading control (1/200; Abcam).
Secondary antibodies were HRP-conjugated with a goat anti-mouse IgG (1/1000;
Abcam) and blots were developed with the ECL reagent (GE Healthcare) and
exposed to film (Kodak).
Immunoassays. To detect apoptosis, transduced A673 cells were seeded onto glass
coverslips coated with poly-L-lysine (Cultek). After 72 h, cells were washed twice
with PBS (Sigma-Aldrich), fixed in 4% paraformaldehyde (PFA; Electron Micro-
scope Sci) for 12 min at room temperature (RT), permeabilized with 0.3% Triton
X-100 (Sigma-Aldrich) in PBS and blocked with 3% normal goat serum (NGS;
Sigma-Aldrich) in PBS for 1 h at RT. Thereafter, samples were incubated overnight
at 4 °C with an anti-caspase-3 antibody (1/200; BD) diluted in PBS supplemented
with 1% NGS, and then with an Alexa Fluor-594-conjugated secondary antibody
(1/500; ThermoFisher Scientific) for 1 h at RT. Finally, samples were counter-
stained with DAPI (Vector Labs), air dried and mounted in Vectashield mounting
medium (Vector Labs). Images were acquired on a Leica DM5500B microscope
(Leica Microsystems) with two lasers with excitation at 594 nm (red channel,
caspase-3 detection) and 405 nm (blue channel, nuclear DAPI staining). Data were
collected sequentially at a resolution of 1024 × 1024 pixels and are representative of
every experiment analyzed using Cytovision v7.4 software (Leica Biosystems).
Tumor tissues were fixed with 4% PFA (Electron Microscopy Sci) in PBS
overnight at 4 °C for immunohistochemistry assays58. Tissue sections were
deparaffinized, rehydrated, blocked with 3% hydrogen peroxide (Merck) and
subjected to heat-induced antigen retrieval. The following antibodies were used at
the indicated dilutions: mouse anti-Ki-67 (DAKO; 1:1.000); rabbit anti-cleaved
caspase-3 (1:800); rabbit anti-GFP (1:1000), mouse anti-Cas9 (1:1000) and Rabbit
anti-CD45 (D3F8Q) (1:200) (all from Cell Signaling Technology). Immunostained
tissue images were examined with an Olympus AX70 microscope and processed
with ImageJ to estimate the labeling index (percentage of positively stained
nuclear area).
Karyotyping. Cell cultures were arrested in metaphase by incubation with Kar-
yoMAX Colcemid (Gibco; 0.1 mg/mL). Cells were treated with a hypotonic solu-
tion (0.075M KCl in ddH2O; Merck) for 30 min at 37 °C and were then fixed with
Carnoy’s solution (methanol and acetic acid 3:1; Sigma-Aldrich). For GTG
banding, slides were trypsinized (ThermoFisher Scientific) and stained with
Giemsa (ThermoFisher Scientific). Metaphase spreads were analyzed on a Zeiss
Axioplan microscope with Ikaros v5.20 karyotyping platform (Metasystems
GmbH). Between 40 and 100 metaphases were analyzed.
Comparative genomic hybridization arrays. Comparative genome hybridization
analysis was performed on a dual color oligonucleotide-based array (SurePrint G3
Human CGH Array 8 × 60 K; Agilent) with a 41 kb overall median probe spacing
(Agilent). Sample and reference DNA (Agilent) samples were labeled with Cy5 and
Cy3 dyes (Agilent), respectively. Hybridization was performed according to the
manufacturer’s protocols. Arrays were scanned using the G2565BA DNA Micro-
array Scanner (Agilent Technologies) and data were extracted using Feature
Extraction Software v10.7 (Agilent Technologies). The Aberration Detection
Method 2 (ADM-2) algorithm in Cytogenomics v5.0 (Agilent Technologies) was
used to identify contiguous genomic regions corresponding to chromosomal
aberrations or copy number variations, which were scored based on the average
quality weighted log ratio of the sample and reference channels.
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Fluorescence in situ hybridization. The EWSR1 break-apart (Kreatech), EWSR1-
FLI1 dual-fusion (Cytocell) and BCR-ABL1 dual-fusion FISH probe (Kreatech)
FISH probes were used to detect t(11;22) and t(9;22) chromosomal translocations.
Tissue sections (5 mm) were deparaffinized in xylene and rehydrated in ethanol
(Sigma-Aldrich). Tissue sections were pre-treated in 2-[N-morpholino] ethane-
sulphonic acid (DAKO), followed by pepsin digestion (DAKO). After dehydration,
the samples were denatured in the presence of the appropriate probe at 66 °C for
10 min and left overnight for hybridization at 37 °C in a hybridizer machine
(DAKO). The slides were then washed with 20xSSC/Tween20 buffer at 63 °C and
mounted on fluorescence mounting medium (with DAPI). FISH signals were
manually scored by counting the number of nuclei with split signals across the
tissue. FISH images were captured using a CCD camera (Photometrics SenSys
camera) connected to a PC running the Zytovision image analysis system (Applied
Imaging Ltd., UK).
Targeted deep sequencing. Potential off-target sites were predicted using the
CRISPR Design web server (http://crispr.mit.edu)53, and Cas-OFFinder (http://
www.rgenome.net/cas-offinder/)59. Customized PCR primers for the on-target and
top-50 potential off-target sites to amplify the sgRNA target region were ordered
from IDT with rhAmpSeq index sequences (Supplementary Table 1). Each locus
was individually amplified using genomic DNA extracted from the relevant cells.
First PCR was performed rhAmpSeq Library Kit (IDT) under the following con-
ditions: 95 °C for 10 min, 10 cycles of 95 °C for 15 s and 61 °C for 4 min and 99.5 °C
for 15 min. PCR products of all potential off-target loci were subsequently equally
pooled and purified with Agencourt AMPure XP beads (Beckman). The PCR
products were then subjected to a second PCR with Illumina indexed adaptor
primers under the following PCR conditions: 95 °C for 3 min, 18 cycles of 95 °C for
15 s, 60 °C for 30 s and 72 °C for 30 s, and 72 °C for 1 min. Second PCR products
were purified with Agencourt AMPure XP beads (Beckman) at a PCR product:bead
ratio of 1:1. The purified libraries were quantified and sequenced using a 300-bp
paired-end cycle on the Illumina MiSeq sequencing platform. Results were ana-
lyzed with CRISPR RGEN Tools Cas-Analyser software60.
Animal experiments. All experiments with mice conformed to Animal Welfare
guidelines and were performed in accordance to protocols approved by the Ethics
Committee of the Instituto de Salud Carlos III. Tumors were generated in 8-week-
old athymic nude (Hds:Athymic Nude-Foxn1 nu) female mice (Charles River) by
subcutaneous implantation of 7.5 × 105 cells in BD Matrigel (volume ratio 1:1).
PDX models were established from patient biopsies (HSJD-ES-006, HSJD-ES-013,
HSJD-ES-018) at Sant Joan de Déu Hospital (Barcelona, Spain). Cells were
implanted into the flanks of 8-week-old athymic nude mice. Tumor growth was
measured blinded to the experimental conditions at the indicated time intervals.
Tumor volume was estimated using a caliper and calculated as volume (mm3)=
(length [mm]) × (width [mm])2 × 0.52. When tumors reached ~150 mm3, mice
were separated blinded to the experimental groups and treated accordingly. Ade-
noviral inoculation consisted of a total of 2.5 × 109 pfu (100 μL total volume)
administered in 3/4 doses every 3 days. Two doses, one per week, of 1.5 mg/kg of
doxorubicin ([DOX], S1208, Selleckchem) were administered in xenografted mice.
In some experiments, when tumors reached 1500 mm3 in size, mice were eutha-
nized and tumors were surgically excised and processed for histopathology.
Adenovirus production. Viral vectors and viruses were constructed and produced
by the Universitat Autonoma de Barcelona (UAB) viral vector production unit.
Briefly, homologous recombination in E. coli between shuttle plasmids and full-
length adenovirus backbones (E1-deleted) were used for the generation of
recombinant adenoviral vectors genomes. The adenovirus genomes were trans-
fected to generate a recombinant adenoviral vector in permissive human cells, and
purified by two sequential CsCl gradient centrifugations and subjected to chro-
matography to eliminate the CsCl and exchange buffers. Viral titers were calculated
and were between 1011 and 1012 particles/ml. Finally, the viral stocks were char-
acterized through the quantification of viral particle content and infectivity. Viral
aliquots were stored at −80 °C before injection.
Electroporation. The Neon Transfection System (Thermo Fisher Scientific) was
used for cell electroporation34. Confluent K562 cells were passed into fresh media
24 h prior to electroporation at a low density; the next day cells were resuspended
in T solution and electroporated using the established conditions by the manu-
facturer: 10 μL tips were used to electroporate 4 × 105 cells with four 10-ms pulses
at 1350 V. After electroporation, cells were seeded in 24-well plates containing pre-
warmed medium.
WST-1 measurement. For the chemotherapy study, 0.05 μg/ml of doxorubicin
([DOX], S1208, Selleckchem), and 0.105 μg/ml of imatinib ([IM], S2475, Sell-
eckchem) were used for in vitro assays of Ewing sarcoma and CML, respectively.
WST-1 measurements were performed according to the standard protocol of the
manufacturer. Briefly, A673 or K562 cells (10,000/well) were cultured in 96-well
plates and overnight. The next day, doxorubicin or imatinib were added to A673
and K562 cells, respectively, and plates were incubated for 24 h. Then 10 μl of
WST-1 was added and plates were incubated for a further 3 h at 37 °C in the
incubator. The absorbance was monitored at 450 nm.
Statistical analysis. Statistical analysis was performed using GraphPad Prism
software package (version 7.0, GraphPad Software). Data from three or more
independent experiments were analyzed by two-tailed Student’s unpaired t-test.
Statistical details of the experiments can be found in the corresponding figure
legends. To flag levels of significance, asterisks were used as follow (*) p-value less
or equal than 0.05, (**) p-value ≤ 0.01, and (***) p-value ≤ 0.001 and (ns) was used
when non-significant differences were observed.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The NGS data have been deposited in the BioProject database under the accession code
PRJNA659633. All other data supporting the findings of this study are available within
the article and its Supplementary Information files and from the corresponding author
upon reasonable request.
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